The DOI matches its Crossref record; 420 of the 420 references it cites were found in a registry or an index.
Alternative‐splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics
Open accessAbstract
Defects in alternative splicing are frequently found in human tumors and result either from mutations in splicing‐regulatory elements of specific cancer genes or from changes in the regulatory splicing machinery. RNA splicing regulators have emerged as a new class of oncoproteins and tumor suppressors, and contribute to disease progression by modulating RNA isoforms involved in the hallmark cancer pathways. Thus, dysregulation of alternative RNA splicing is fundamental to cancer and provides a potentially rich source of novel therapeutic targets. Here, we review the alterations in splicing regulatory factors detected in human tumors, as well as the resulting alternatively spliced isoforms that impact cancer hallmarks, and discuss how they contribute to disease pathogenesis. RNA splicing is a highly regulated process and, as such, the regulators are themselves tightly regulated. Differential transcriptional and posttranscriptional regulation of splicing factors modulates their levels and activities in tumor cells. Furthermore, the composition of the tumor microenvironment can also influence which isoforms are expressed in a given cell type and impact drug responses. Finally, we summarize current efforts in targeting alternative splicing, including global splicing inhibition using small molecules blocking the spliceosome or splicing‐factor‐modifying enzymes, as well as splice‐switching RNA‐based therapeutics to modulate cancer‐specific splicing isoforms. This article is categorized under: RNA in Disease and Development > RNA in Disease RNA Processing > Splicing Regulation/Alternative Splicing
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: hnRNP K: An HDM2 Target and Transcriptional Coactivator of p53 in Response to DNA Damage
Moumen, A., Masterson, P., O'Connor, M. J., & Jackson, S. P. (2005) · Cell · doi:10.1016/j.cell.2005.09.032 · Cited by 350
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death
Boise, L. H., González-García, M., Postema, C. E., Ding, L., Lindsten, T., Turka, L. A., Mao, X., Nuñez, G., & Thompson, C. B. (1993) · Cell · doi:10.1016/0092-8674(93)90508-n · Cited by 3,087
The extracellular matrix: A dynamic niche in cancer progression
Lu, P., Weaver, V. M., & Werb, Z. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201102147 · Cited by 3,024
The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth
Christofk, H. R., Vander Heiden, M. G., Harris, M. H., Ramanathan, A., Gerszten, R. E., Wei, R., Fleming, M. D., Schreiber, S. L., & Cantley, L. C. (2008) · Nature · doi:10.1038/nature06734 · Cited by 2,820
Tripathi, V., Ellis, J. D., Shen, Z., Song, D. Y., Pan, Q., Watt, A. T., Freier, S. M., Bennett, C. F., Sharma, A., Bubulya, P. A., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.08.011 · Cited by 2,219
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
Initiative, A. P. C. G., Biankin, A. V., Waddell, N., Kassahn, K. S., Gingras, M.-C., Muthuswamy, L. B., Johns, A. L., Miller, D. K., Wilson, P. J., Patch, A.-M., et al. (2012) · Nature · doi:10.1038/nature11547 · Cited by 2,058 · cited 2×
“Additionally, the K700E mutation is detected in 3% of pancreatic and 1.8% of breast cancers, both of which exhibit alterations in RNA splicing patterns (Biankin et al., 2012; Maguire et al., 2015).”
BackgroundInfluentialFrequent pathway mutations of splicing machinery in myelodysplasia
Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R., Sato, Y., Sato-Otsubo, A., Kon, A., Nagasaki, M., et al. (2011) · Nature · doi:10.1038/nature10496 · Cited by 2,029
Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
Imielinski, M., Berger, A. H., Hammerman, P. S., Hernandez, B., Pugh, T. J., Hodis, E., Cho, J., Suh, J., Capelletti, M., Sivachenko, A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.029 · Cited by 1,789
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454
Bennett, C. F., & Swayze, E. E. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105654 · Cited by 1,374
Houck, K. A., Ferrara, N., Winer, J., Cachianes, G., Li, B., & Leung, D. W. (1991) · Molecular Endocrinology · doi:10.1210/mend-5-12-1806 · Cited by 1,365
Sotillo, E., Barrett, D. M., Black, K. L., Bagashev, A., Oldridge, D., Wu, G., Sussman, R., Lanauze, C., Ruella, M., Gazzara, M. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1020 · Cited by 1,254
Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts
Papaemmanuil, E., Cazzola, M., Boultwood, J., Malcovati, L., Vyas, P., Bowen, D., Pellagatti, A., Wainscoat, J. S., Hellstrom-Lindberg, E., Gambacorti-Passerini, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103283 · Cited by 1,222
Single-cell transcriptomics reveals bimodality in expression and splicing in immune cells
Shalek, A. K., Satija, R., Adiconis, X., Gertner, R. S., Gaublomme, J. T., Raychowdhury, R., Schwartz, S., Yosef, N., Malboeuf, C., Lu, D., et al. (2013) · Nature · doi:10.1038/nature12172 · Cited by 1,190
HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer
David, C. J., Chen, M., Assanah, M., Canoll, P., & Manley, J. L. (2010) · Nature · doi:10.1038/nature08697 · Cited by 1,179
Bim: a novel member of the Bcl-2 family that promotes apoptosis
O'Connor, L. (1998) · The EMBO Journal · doi:10.1093/emboj/17.2.384 · Cited by 1,166
RNA therapeutics: beyond RNA interference and antisense oligonucleotides
Kole, R., Krainer, A. R., & Altman, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3625 · Cited by 1,152
The SR protein family of splicing factors: master regulators of gene expression
Long, J. C., & Caceres, J. F. (2009) · Biochemical Journal · doi:10.1042/bj20081501 · Cited by 1,137
Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
Witkiewicz, A. K., McMillan, E. A., Balaji, U., Baek, G., Lin, W.-C., Mansour, J., Mollaee, M., Wagner, K.-U., Koduru, P., Yopp, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms7744 · Cited by 1,115 · cited 2×
“Conversely, in pancreatic cancer, RBM10 mutations are associated with longer survival in spite of histological features of aggressive disease (Witkiewicz et al., 2015).”
BackgroundProtection from Fas-Mediated Apoptosis by a Soluble Form of the Fas Molecule
Cheng, J., Zhou, T., Liu, C., Shapiro, J. P., Brauer, M. J., Kiefer, M. C., Barr, P. J., & Mountz, J. D. (1994) · Science · doi:10.1126/science.7510905 · Cited by 1,107
The hnRNP family: insights into their role in health and disease
Geuens, T., Bouhy, D., & Timmerman, V. (2016) · Human Genetics · doi:10.1007/s00439-016-1683-5 · Cited by 1,093
SF3B1 and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia
Wang, L., Lawrence, M. S., Wan, Y., Stojanov, P., Sougnez, C., Stevenson, K., Werner, L., Sivachenko, A., DeLuca, D. S., Zhang, L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1109016 · Cited by 1,080
Lewis, B. P., Green, R. E., & Brenner, S. E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0136770100 · Cited by 1,067
Quesada, V., Conde, L., Villamor, N., Ordóñez, G. R., Jares, P., Bassaganyas, L., Ramsay, A. J., Beà, S., Pinyol, M., Martínez-Trillos, A., et al. (2012) · Nature Genetics · doi:10.1038/ng.1032 · Cited by 996
The gene encoding the splicing factor SF2/ASF is a proto-oncogene
Karni, R., de Stanchina, E., Lowe, S. W., Sinha, R., Mu, D., & Krainer, A. R. (2007) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1209 · Cited by 934
Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma
Giannakis, M., Mu, X. J., Shukla, S. A., Qian, Z. R., Cohen, O., Nishihara, R., Bahl, S., Cao, Y., Amin-Mansour, A., Yamauchi, M., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.075 · Cited by 913
Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma
Robertson, A. G., Shih, J., Yau, C., Gibb, E. A., Oba, J., Mungall, K. L., Hess, J. M., Uzunangelov, V., Walter, V., Danilova, L., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.003 · Cited by 887
The delivery of therapeutic oligonucleotides
Juliano, R. L. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw236 · Cited by 854
Palucka, A. K., & Coussens, L. M. (2016) · Cell · doi:10.1016/j.cell.2016.01.049 · Cited by 843
Wang, L., Miura, M., Bergeron, L., Zhu, H., & Yuan, J. (1994) · Cell · doi:10.1016/s0092-8674(94)90422-7 · Cited by 836
Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis
Anastasiou, D., Yu, Y., Israelsen, W. J., Jiang, J.-K., Boxer, M. B., Hong, B. S., Tempel, W., Dimov, S., Shen, M., Jha, A., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.1060 · Cited by 816
Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15
Han, T., Goralski, M., Gaskill, N., Capota, E., Kim, J., Ting, T. C., Xie, Y., Williams, N. S., & Nijhawan, D. (2017) · Science · doi:10.1126/science.aal3755 · Cited by 762
Regulation of alternative pre-mRNA splicing by hnRNP A1 and splicing factor SF2
Mayeda, A., & Krainer, A. R. (1992) · Cell · doi:10.1016/0092-8674(92)90477-t · Cited by 735
Unproductive splicing of SR genes associated with highly conserved and ultraconserved DNA elements
Lareau, L. F., Inada, M., Green, R. E., Wengrod, J. C., & Brenner, S. E. (2007) · Nature · doi:10.1038/nature05676 · Cited by 681
Defects in regulation of apoptosis in caspase-2-deficient mice
Bergeron, L., Perez, G. I., Macdonald, G., Shi, L., Sun, Y., Jurisicova, A., Varmuza, S., Latham, K. E., Flaws, J. A., Salter, J. C. M., et al. (1998) · Genes & Development · doi:10.1101/gad.12.9.1304 · Cited by 681
Brown, R. L., Reinke, L. M., Damerow, M. S., Perez, D., Chodosh, L. A., Yang, J., & Cheng, C. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44540 · Cited by 631
Results from a phase 1 study of nusinersen (ISIS-SMN Rx ) in children with spinal muscular atrophy
Chiriboga, C. A., Swoboda, K. J., Darras, B. T., Iannaccone, S. T., Montes, J., De Vivo, D. C., Norris, D. A., Bennett, C. F., & Bishop, K. M. (2016) · Neurology · doi:10.1212/wnl.0000000000002445 · Cited by 612
Pyruvate kinase: Function, regulation and role in cancer
Israelsen, W. J., & Vander Heiden, M. G. (2015) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2015.08.004 · Cited by 589
Cellular uptake and trafficking of antisense oligonucleotides
Crooke, S. T., Wang, S., Vickers, T. A., Shen, W., & Liang, X.-H. (2017) · Nature Biotechnology · doi:10.1038/nbt.3779 · Cited by 582
Colwill, K., Pawson, T., Andrews, B., Prasad, J., Manley, J. L., Bell, J. C., & Duncan, P. I. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00357.x · Cited by 580
ESRP1 and ESRP2 Are Epithelial Cell-Type-Specific Regulators of FGFR2 Splicing
Warzecha, C. C., Sato, T. K., Nabet, B., Hogenesch, J. B., & Carstens, R. P. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.01.025 · Cited by 579
SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition
Kim, E., Ilagan, J. O., Liang, Y., Daubner, G. M., Lee, S. C.-W., Ramakrishnan, A., Li, Y., Chung, Y. R., Micol, J.-B., Murphy, M. E., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.04.006 · Cited by 575
Therapeutic targeting of splicing in cancer
Lee, S. C.-W., & Abdel-Wahab, O. (2016) · Nature Medicine · doi:10.1038/nm.4165 · Cited by 561
Ng, K. P., Hillmer, A. M., Chuah, C. T. H., Juan, W. C., Ko, T. K., Teo, A. S. M., Ariyaratne, P. N., Takahashi, N., Sawada, K., Fei, Y., et al. (2012) · Nature Medicine · doi:10.1038/nm.2713 · Cited by 557
The Functional Impact of Alternative Splicing in Cancer
Climente-González, H., Porta-Pardo, E., Godzik, A., & Eyras, E. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.08.012 · Cited by 552
(2002) · PubMed · Cited by 550
PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells
Israelsen, W. J., Dayton, T. L., Davidson, S. M., Fiske, B. P., Hosios, A. M., Bellinger, G., Li, J., Yu, Y., Sasaki, M., Horner, J. W., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.025 · Cited by 549 · cited 1×
“However, other studies suggest that PKM2 is not necessary for tumor growth in colon cancer cell lines or in a breast cancer mouse model (CortesCros et al., 2013; Israelsen et al., 2013; Lau et al., 2017).”
BackgroundNi, J. Z., Grate, L., Donohue, J. P., Preston, C., Nobida, N., O’Brien, G., Shiue, L., Clark, T. A., Blume, J. E., & Ares, M. (2007) · Genes & Development · doi:10.1101/gad.1525507 · Cited by 549
Martin, M., Maßhöfer, L., Temming, P., Rahmann, S., Metz, C., Bornfeld, N., van de Nes, J., Klein-Hitpass, L., Hinnebusch, A. G., Horsthemke, B., et al. (2013) · Nature Genetics · doi:10.1038/ng.2674 · Cited by 542
Splice-switching antisense oligonucleotides as therapeutic drugs
Havens, M. A., & Hastings, M. L. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw533 · Cited by 538
Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma
Harbour, J. W., Roberson, E. D. O., Anbunathan, H., Onken, M. D., Worley, L. A., & Bowcock, A. M. (2013) · Nature Genetics · doi:10.1038/ng.2523 · Cited by 516
PKM2, cancer metabolism, and the road ahead
Dayton, T. L., Jacks, T., & Vander Heiden, M. G. (2016) · The EMBO Reports · doi:10.15252/embr.201643300 · Cited by 515
VEGF-A splicing: the key to anti-angiogenic therapeutics?
Harper, S. J., & Bates, D. O. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2505 · Cited by 514
Malcovati, L., Papaemmanuil, E., Bowen, D. T., Boultwood, J., Della Porta, M. G., Pascutto, C., Travaglino, E., Groves, M. J., Godfrey, A. L., Ambaglio, I., et al. (2011) · Blood · doi:10.1182/blood-2011-09-377275 · Cited by 498
The spliceosome is a therapeutic vulnerability in MYC-driven cancer
Hsu, T. Y.-T., Simon, L. M., Neill, N. J., Marcotte, R., Sayad, A., Bland, C. S., Echeverria, G. V., Sun, T., Kurley, S. J., Tyagi, S., et al. (2015) · Nature · doi:10.1038/nature14985 · Cited by 492
Shapiro, I. M., Cheng, A. W., Flytzanis, N. C., Balsamo, M., Condeelis, J. S., Oktay, M. H., Burge, C. B., & Gertler, F. B. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1002218 · Cited by 461
Chaffer, C. L., Brennan, J. P., Slavin, J. L., Blick, T., Thompson, E. W., & Williams, E. D. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2044 · Cited by 455
Darman, R. B., Seiler, M., Agrawal, A. A., Lim, K. H., Peng, S., Aird, D., Bailey, S. L., Bhavsar, E. B., Chan, B., Colla, S., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.09.053 · Cited by 453
VEGF165b, an Inhibitory Vascular Endothelial Growth Factor Splice Variant
Woolard, J., Wang, W.-Y., Bevan, H. S., Qiu, Y., Morbidelli, L., Pritchard-Jones, R. O., Cui, T.-G., Sugiono, M., Waine, E., Perrin, R., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0934 · Cited by 451
Anczuków, O., Rosenberg, A. Z., Akerman, M., Das, S., Zhan, L., Karni, R., Muthuswamy, S. K., & Krainer, A. R. (2012) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2207 · Cited by 447
Self-citationHong, D., Kurzrock, R., Kim, Y., Woessner, R., Younes, A., Nemunaitis, J., Fowler, N., Zhou, T., Schmidt, J., Jo, M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5272 · Cited by 445
Furukawa, T., Kuboki, Y., Tanji, E., Yoshida, S., Hatori, T., Yamamoto, M., Shibata, N., Shimizu, K., Kamatani, N., & Shiratori, K. (2011) · Scientific Reports · doi:10.1038/srep00161 · Cited by 440
Detained introns are a novel, widespread class of post-transcriptionally spliced introns
Boutz, P. L., Bhutkar, A., & Sharp, P. A. (2015) · Genes & Development · doi:10.1101/gad.247361.114 · Cited by 425
Clower, C. V., Chatterjee, D., Wang, Z., Cantley, L. C., Vander Heiden, M. G., & Krainer, A. R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914845107 · Cited by 424
Dynamic Protein-Protein Interaction Wiring of the Human Spliceosome
Hegele, A., Kamburov, A., Grossmann, A., Sourlis, C., Wowro, S., Weimann, M., Will, C. L., Pena, V., Lührmann, R., & Stelzl, U. (2012) · Molecular Cell · doi:10.1016/j.molcel.2011.12.034 · Cited by 414
The spliceosome as a target of novel antitumour drugs
Bonnal, S., Vigevani, L., & Valcárcel, J. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3823 · Cited by 405
Yan, G., Fukabori, Y., McBride, G., Nikolaropolous, S., & McKeehan, W. L. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.8.4513 · Cited by 403
Selective degradation of splicing factor CAPERα by anticancer sulfonamides
Uehara, T., Minoshima, Y., Sagane, K., Sugi, N. H., Mitsuhashi, K. O., Yamamoto, N., Kamiyama, H., Takahashi, K., Kotake, Y., Uesugi, M., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2363 · Cited by 396
Cell Motility Is Controlled by SF2/ASF through Alternative Splicing of the Ron Protooncogene
Ghigna, C., Giordano, S., Shen, H., Benvenuto, F., Castiglioni, F., Comoglio, P. M., Green, M. R., Riva, S., & Biamonti, G. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.10.026 · Cited by 389
BIN1 is a novel MYC–interacting protein with features of a tumour suppressor
Sakamuro, D., Elliott, K. J., Wechsler-Reya, R., & Prendergast, G. C. (1996) · Nature Genetics · doi:10.1038/ng0996-69 · Cited by 387
Alsafadi, S., Houy, A., Battistella, A., Popova, T., Wassef, M., Henry, E., Tirode, F., Constantinou, A., Piperno-Neumann, S., Roman-Roman, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms10615 · Cited by 386
An ESRP‐regulated splicing programme is abrogated during the epithelial–mesenchymal transition
Warzecha, C. C., Jiang, P., Amirikian, K., Dittmar, K. A., Lu, H., Shen, S., Guo, W., Xing, Y., & Carstens, R. P. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.195 · Cited by 383
Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell
Yae, T., Tsuchihashi, K., Ishimoto, T., Motohara, T., Yoshikawa, M., Yoshida, G. J., Wada, T., Masuko, T., Mogushi, K., Tanaka, H., et al. (2012) · Nature Communications · doi:10.1038/ncomms1892 · Cited by 383
Obeng, E. A., Chappell, R. J., Seiler, M., Chen, M. C., Campagna, D. R., Schmidt, P. J., Schneider, R. K., Lord, A. M., Wang, L., Gambe, R. G., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.08.006 · Cited by 380
MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis
Koh, C. M., Bezzi, M., Low, D. H. P., Ang, W. X., Teo, S. X., Gay, F. P. H., Al-Haddawi, M., Tan, S. Y., Osato, M., Sabò, A., et al. (2015) · Nature · doi:10.1038/nature14351 · Cited by 380
Bechara, E. G., Sebestyén, E., Bernardis, I., Eyras, E., & Valcárcel, J. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.11.010 · Cited by 372
Rossi, D., Bruscaggin, A., Spina, V., Rasi, S., Khiabanian, H., Messina, M., Fangazio, M., Vaisitti, T., Monti, S., Chiaretti, S., et al. (2011) · Blood · doi:10.1182/blood-2011-08-373159 · Cited by 369
SRSF1-Regulated Alternative Splicing in Breast Cancer
Anczuków, O., Akerman, M., Cléry, A., Wu, J., Shen, C., Shirole, N. H., Raimer, A., Sun, S., Jensen, M. A., Hua, Y., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.09.005 · Cited by 367
Self-citationRegulation of Fas Alternative Splicing by Antagonistic Effects of TIA-1 and PTB on Exon Definition
Izquierdo, J. M., Majós, N., Bonnal, S., Martínez, C., Castelo, R., Guigó, R., Bilbao, D., & Valcárcel, J. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.06.015 · Cited by 364
The significant other: splicing by the minor spliceosome
Turunen, J. J., Niemelä, E. H., Verma, B., & Frilander, M. J. (2013) · WIREs RNA · doi:10.1002/wrna.1141 · Cited by 349
Schnelzer, A., Prechtel, D., Knaus, U., Dehne, K., Gerhard, M., Graeff, H., Harbeck, N., Schmitt, M., & Lengyel, E. (2000) · Oncogene · doi:10.1038/sj.onc.1203621 · Cited by 347
PKM2 promotes tumor angiogenesis by regulating HIF-1α through NF-κB activation
Azoitei, N., Becher, A., Steinestel, K., Rouhi, A., Diepold, K., Genze, F., Simmet, T., & Seufferlein, T. (2016) · Molecular Cancer · doi:10.1186/s12943-015-0490-2 · Cited by 336
The RNA-binding protein Sam68 modulates the alternative splicing of Bcl-x
Paronetto, M. P., Achsel, T., Massiello, A., Chalfant, C. E., & Sette, C. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200701005 · Cited by 334
An Alternative Splicing Network Links Cell-Cycle Control to Apoptosis
Moore, M. J., Wang, Q., Kennedy, C. J., & Silver, P. A. (2010) · Cell · doi:10.1016/j.cell.2010.07.019 · Cited by 316
SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML)
Meggendorfer, M., Roller, A., Haferlach, T., Eder, C., Dicker, F., Grossmann, V., Kohlmann, A., Alpermann, T., Yoshida, K., Ogawa, S., et al. (2012) · Blood · doi:10.1182/blood-2012-01-404863 · Cited by 311
SC35 autoregulates its expression by promoting splicing events that destabilize its mRNAs
Sureau, A. (2001) · The EMBO Journal · doi:10.1093/emboj/20.7.1785 · Cited by 310
DNA Damage Regulates Alternative Splicing through Inhibition of RNA Polymerase II Elongation
Muñoz, M. J., Santangelo, M. S. P., Paronetto, M. P., de la Mata, M., Pelisch, F., Boireau, S., Glover-Cutter, K., Ben-Dov, C., Blaustein, M., Lozano, J. J., et al. (2009) · Cell · doi:10.1016/j.cell.2009.03.010 · Cited by 310
Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms.
Fox, S. B., Fawcett, J., Jackson, D. G., Collins, I., Gatter, K. C., Harris, A. L., Gearing, A. J. H., & Simmons, D. L. (1994) · PubMed · Cited by 304
Splicing-factor alterations in cancers
Anczuków, O., & Krainer, A. R. (2016) · RNA · doi:10.1261/rna.057919.116 · Cited by 302
Self-citationCorrection of disease-associated exon skipping by synthetic exon-specific activators
Cartegni, L., & Krainer, A. R. (2003) · Nature Structural Biology · doi:10.1038/nsb887 · Cited by 301
Emerging Functions of SRSF1, Splicing Factor and Oncoprotein, in RNA Metabolism and Cancer
Das, S., & Krainer, A. R. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0131 · Cited by 298
Bae, J., Leo, C. P., Hsu, S. Y., & Hsueh, A. J. W. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m909826199 · Cited by 289
BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors
Faber, A. C., Corcoran, R. B., Ebi, H., Sequist, L. V., Waltman, B. A., Chung, E., Incio, J., Digumarthy, S. R., Pollack, S. F., Song, Y., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0106 · Cited by 283
MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism
Bandopadhayay, P., Ramkissoon, L. A., Jain, P., Bergthold, G., Wala, J., Zeid, R., Schumacher, S. E., Urbanski, L., O'Rourke, R., Gibson, W. J., et al. (2016) · Nature Genetics · doi:10.1038/ng.3500 · Cited by 277
Self-citationSebestyén, E., Singh, B., Miñana, B., Pagès, A., Mateo, F., Pujana, M. A., Valcárcel, J., & Eyras, E. (2016) · Genome Research · doi:10.1101/gr.199935.115 · Cited by 276
Zhou, Z., Qiu, J., Liu, W., Zhou, Y., Plocinik, R. M., Li, H., Hu, Q., Ghosh, G., Adams, J. A., Rosenfeld, M. G., et al. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.05.014 · Cited by 273
The splicing factor SRp20 modifies splicing of its own mRNA and ASF/SF2 antagonizes this regulation
Jumaa, H. (1997) · The EMBO Journal · doi:10.1093/emboj/16.16.5077 · Cited by 272
A Mena Invasion Isoform Potentiates EGF-Induced Carcinoma Cell Invasion and Metastasis
Philippar, U., Roussos, E. T., Oser, M., Yamaguchi, H., Kim, H.-D., Giampieri, S., Wang, Y., Goswami, S., Wyckoff, J. B., Lauffenburger, D. A., et al. (2008) · Developmental Cell · doi:10.1016/j.devcel.2008.09.003 · Cited by 269
Wang, Y., Bernhardy, A. J., Cruz, C., Krais, J. J., Nacson, J., Nicolas, E., Peri, S., van der Gulden, H., van der Heijden, I., O'Brien, S. W., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0186 · Cited by 269
An Atomic Structure of the Human Spliceosome
Zhang, X., Yan, C., Hang, J., Finci, L. I., Lei, J., & Shi, Y. (2017) · Cell · doi:10.1016/j.cell.2017.04.033 · Cited by 269
Transportin-SR, a Nuclear Import Receptor for SR Proteins
Kataoka, N., Bachorik, J. L., & Dreyfuss, G. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.145.6.1145 · Cited by 265
Cryo-EM Structure of a Pre-catalytic Human Spliceosome Primed for Activation
Bertram, K., Agafonov, D. E., Dybkov, O., Haselbach, D., Leelaram, M. N., Will, C. L., Urlaub, H., Kastner, B., Lührmann, R., & Stark, H. (2017) · Cell · doi:10.1016/j.cell.2017.07.011 · Cited by 265
Corrionero, A., Miñana, B., & Valcárcel, J. (2011) · Genes & Development · doi:10.1101/gad.2014311 · Cited by 263
Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma
Giannakis, M., Mu, X. J., Shukla, S. A., Qian, Z. R., Cohen, O., Nishihara, R., Bahl, S., Cao, Y., Amin-Mansour, A., Yamauchi, M., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.10.009 · Cited by 259
Calabretta, S., Bielli, P., Passacantilli, I., Pilozzi, E., Fendrich, V, Capurso, G., Fave, G. D., & Sette, C. (2016) · Oncogene · doi:10.1038/onc.2015.270 · Cited by 249
Concerted regulation of nuclear and cytoplasmic activities of SR proteins by AKT
Blaustein, M., Pelisch, F., Tanos, T., Muñoz, M. J., Wengier, D., Quadrana, L., Sanford, J. R., Muschietti, J. P., Kornblihtt, A. R., Cáceres, J. F., et al. (2005) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1020 · Cited by 246
Screaton, G. R., Bell, M. V., Bell, J. I., & Jackson, D. G. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)31376-0 · Cited by 243
Genomic Landscape Survey Identifies SRSF1 as a Key Oncodriver in Small Cell Lung Cancer
Jiang, L., Huang, J., Higgs, B. W., Hu, Z., Xiao, Z., Yao, X., Conley, S., Zhong, H., Liu, Z., Brohawn, P., et al. (2016) · PLOS Genetics · doi:10.1371/journal.pgen.1005895 · Cited by 241
Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome
Madan, V., Kanojia, D., Li, J., Okamoto, R., Sato-Otsubo, A., Kohlmann, A., Sanada, M., Grossmann, V., Sundaresan, J., Shiraishi, Y., et al. (2015) · Nature Communications · doi:10.1038/ncomms7042 · Cited by 240
An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene.
Lu, F., Gladden, A. B., & Diehl, J. A. (2003) · PubMed · Cited by 239
The RNA-Binding Protein QKI Suppresses Cancer-Associated Aberrant Splicing
Zong, F.-Y., Fu, X., Wei, W.-J., Luo, Y.-G., Heiner, M., Cao, L.-J., Fang, Z., Fang, R., Lu, D., Ji, H., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004289 · Cited by 235
Golan-Gerstl, R., Cohen, M., Shilo, A., Suh, S.-S., Bakàcs, A., Coppola, L., & Karni, R. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4410 · Cited by 232
Varey, A. H. R., Rennel, E. S., Qiu, Y., Bevan, H. S., Perrin, R. M., Raffy, S., Dixon, A. R., Paraskeva, C., Zaccheo, O., Hassan, A. B., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604308 · Cited by 226
Nowak, D. G., Amin, E. M., Rennel, E. S., Hoareau-Aveilla, C., Gammons, M., Damodoran, G., Hagiwara, M., Harper, S. J., Woolard, J., Ladomery, M. R., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.074930 · Cited by 226
Wang, Y., Chen, D., Qian, H., Tsai, Y. S., Shao, S., Liu, Q., Dominguez, D., & Wang, Z. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.07.010 · Cited by 225
Xu, Y., Gao, X. D., Lee, J.-H., Huang, H., Tan, H., Ahn, J., Reinke, L. M., Peter, M. E., Feng, Y., Gius, D., et al. (2014) · Genes & Development · doi:10.1101/gad.241968.114 · Cited by 225
BCL-X expression in multiple myeloma: possible indicator of chemoresistance.
Tu, Y., Renner, S., Xu, F., Fleishman, A. N., Taylor, J. M. G., Weisz, J., Vescio, R. A., Rettig, M. B., Berenson, J., Krajewski, S., et al. (1998) · PubMed · Cited by 222
Solomon, D. A., Wang, Y., Fox, S. R., Lambeck, T. C., Giesting, S., Lan, Z., Senderowicz, A. M., & Knudsen, E. S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303969200 · Cited by 218
Narla, G., DiFeo, A., Reeves, H. L., Schaid, D. J., Hirshfeld, J., Hod, E., Katz, A., Isaacs, W. B., Hebbring, S., Komiya, A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4249 · Cited by 214
Bcl-xL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis.
Dole, M. G., Jasty, R., Cooper, M. J., Thompson, C. B., Núñez, G., & Castle, V. P. (1995) · PubMed · Cited by 214
Zhou, Y.-Q., He, C., Chen, Y.-Q., Wang, D., & Wang, M.-H. (2003) · Oncogene · doi:10.1038/sj.onc.1206075 · Cited by 210
Lai, M.-C., Lin, R.-I., Huang, S.-Y., Tsai, C.-W., & Tarn, W.-Y. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.11.7950 · Cited by 209
TGF-β drives epithelial-mesenchymal transition through δEF1-mediated downregulation of ESRP
Horiguchi, K., Sakamoto, K., Koinuma, D., Semba, K., Inoue, A., Inoue, S., Fujii, H., Yamaguchi, A., Miyazawa, K., Miyazono, K., et al. (2012) · Oncogene · doi:10.1038/onc.2011.493 · Cited by 209
Disease-associated mutation in SRSF2 misregulates splicing by altering RNA-binding affinities
Zhang, J., Lieu, Y. K., Ali, A. M., Penson, A., Reggio, K. S., Rabadan, R., Raza, A., Mukherjee, S., & Manley, J. L. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1514105112 · Cited by 208
Kong, J., Sun, W., Li, C., Wan, L., Wang, S., Wu, Y., Xu, E., Zhang, H., & Lai, M. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.07.015 · Cited by 208
SRp20 is a proto-oncogene critical for cell proliferation and tumor induction and maintenance
Jia, R., Li, C., McCoy, J. P., Deng, C.-X., & Zheng, Z.-M. (2010) · International Journal of Biological Sciences · doi:10.7150/ijbs.6.806 · Cited by 206
CD44v8-10 Is a Cancer-Specific Marker for Gastric Cancer Stem Cells
Lau, W. M., Teng, E., Chong, H. S., Lopez, K. A. P., Tay, A. Y. L., Salto-Tellez, M., Shabbir, A., So, J. B. Y., & Chan, S. L. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2309 · Cited by 206
Ngo, J. C. K., Chakrabarti, S., Ding, J.-H., Velazquez-Dones, A., Nolen, B., Aubol, B. E., Adams, J. A., Fu, X.-D., & Ghosh, G. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.08.025 · Cited by 206
Warzecha, C. C., Shen, S., Xing, Y., & Carstens, R. P. (2009) · RNA Biology · doi:10.4161/rna.6.5.9606 · Cited by 205
Regulation of CD45 Alternative Splicing by Heterogeneous Ribonucleoprotein, hnRNPLL
Oberdoerffer, S., Moita, L. F., Neems, D., Freitas, R. P., Hacohen, N., & Rao, A. (2008) · Science · doi:10.1126/science.1157610 · Cited by 205
Mitra, D., Brumlik, M. J., Okamgba, S. U., Zhu, Y., Duplessis, T. T., Parvani, J. G., Lesko, S. M., Brogi, E., & Jones, F. E. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0295 · Cited by 204
Saltzman, A. L., Kim, Y. K., Pan, Q., Fagnani, M. M., Maquat, L. E., & Blencowe, B. J. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00361-08 · Cited by 204
Oncogenic Splicing Factor SRSF1 Is a Critical Transcriptional Target of MYC
Das, S., Anczuków, O., Akerman, M., & Krainer, A. R. (2012) · Cell Reports · doi:10.1016/j.celrep.2011.12.001 · Cited by 202
Self-citationSF2/ASF autoregulation involves multiple layers of post-transcriptional and translational control
Sun, S., Zhang, Z., Sinha, R., Karni, R., & Krainer, A. R. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1750 · Cited by 201
The Biflavonoid Isoginkgetin Is a General Inhibitor of Pre-mRNA Splicing
O'Brien, K., Matlin, A. J., Lowell, A. M., & Moore, M. J. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m805556200 · Cited by 200
Taylor, J. K., Zhang, Q. Q., Wyatt, J. R., & Dean, N. M. (1999) · Nature Biotechnology · doi:10.1038/15079 · Cited by 197
Nam, J.-M., Onodera, Y., Bissell, M. J., & Park, C. C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2319 · Cited by 196
Dolatshad, H., Pellagatti, A., Fernandez-Mercado, M., Yip, B. H., Malcovati, L., Attwood, M., Przychodzen, B., Sahgal, N., Kanapin, A. A., Lockstone, H., et al. (2015) · Leukemia · doi:10.1038/leu.2014.331 · Cited by 195
Ge, K., DuHadaway, J., Du, W., Herlyn, M., Rodeck, U., & Prendergast, G. C. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.17.9689 · Cited by 195
Bingle, C. D., Craig, R. W., Swales, B. M., Singleton, V., Zhou, P., & Whyte, M. K. B. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m909572199 · Cited by 191
Martinez, N. M., & Lynch, K. W. (2013) · Immunological Reviews · doi:10.1111/imr.12047 · Cited by 190
Tenascin C in metastasis: A view from the invasive front
Lowy, C. M., & Oskarsson, T. (2015) · Cell Adhesion & Migration · doi:10.1080/19336918.2015.1008331 · Cited by 178
A nucleo‐cytoplasmic SR protein functions in viral IRES‐mediated translation initiation
Bedard, K. M., Daijogo, S., & Semler, B. L. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601494 · Cited by 178
Stoilov, P. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh051 · Cited by 177
Collesi, C., Santoro, M. M., Gaudino, G., & Comoglio, P. M. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.10.5518 · Cited by 176
Antitumorigenic potential of STAT3 alternative splicing modulation
Zammarchi, F., de Stanchina, E., Bournazou, E., Supakorndej, T., Martires, K., Riedel, E., Corben, A. D., Bromberg, J. F., & Cartegni, L. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108482108 · Cited by 176
RBM5/Luca-15/H37 Regulates Fas Alternative Splice Site Pairing after Exon Definition
Bonnal, S., Martínez, C., Förch, P., Bachi, A., Wilm, M., & Valcárcel, J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.08.008 · Cited by 176
SF3B1 mutations constitute a novel therapeutic target in breast cancer
Maguire, S. L., Leonidou, A., Wai, P., Marchiò, C., Ng, C. K., Sapino, A., Salomon, A., Reis‐Filho, J. S., Weigelt, B., & Natrajan, R. C. (2015) · The Journal of Pathology · doi:10.1002/path.4483 · Cited by 175
Singh, A., Karnoub, A. E., Palmby, T. R., Lengyel, E., Sondek, J., & Der, C. J. (2004) · Oncogene · doi:10.1038/sj.onc.1208182 · Cited by 174
Antisense oligonucleotide–mediated MDM4 exon 6 skipping impairs tumor growth
Dewaele, M., Tabaglio, T., Willekens, K., Bezzi, M., Teo, S. X., Low, D. H. P., Koh, C. M., Rambow, F., Fiers, M., Rogiers, A., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci82534 · Cited by 173
Loomis, R. J., Naoe, Y., Parker, J. B., Savic, V., Bozovsky, M. R., Macfarlan, T., Manley, J. L., & Chakravarti, D. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.02.003 · Cited by 172
Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity.
Lebedeva, I. V., Rando, R. F., Ojwang, J. O., Cossum, P. A., & Stein, C. A. (2000) · PubMed · Cited by 171
Hayes, G. M., Carrigan, P. E., & Miller, L. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2969 · Cited by 171
Carpenter, B., McKay, M., Dundas, S. R., Lawrie, L. C., Telfer, C., & Murray, G. I. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603349 · Cited by 170
Borsi, L., Carnemolla, B., Nicolò, G., Spina, B., Tanara, G., & Zardi, L. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910520504 · Cited by 168
Sashida, G., Harada, H., Matsui, H., Oshima, M., Yui, M., Harada, Y., Tanaka, S., Mochizuki-Kashio, M., Wang, C., Saraya, A., et al. (2014) · Nature Communications · doi:10.1038/ncomms5177 · Cited by 167
Sudemycins, Novel Small Molecule Analogues of FR901464, Induce Alternative Gene Splicing
Fan, L., Lagisetti, C., Edwards, C. C., Webb, T. R., & Potter, P. M. (2011) · ACS Chemical Biology · doi:10.1021/cb100356k · Cited by 167
Narla, G., DiFeo, A., Yao, S., Banno, A., Hod, E., Reeves, H. L., Qiao, R. F., Camacho-Vanegas, O., Levine, A., Kirschenbaum, A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0217 · Cited by 166
Tang, Y., Horikawa, I., Ajiro, M., Robles, A. I., Fujita, K., Mondal, A. M., Stauffer, J. K., Zheng, Z.-M., & Harris, C. C. (2013) · Oncogene · doi:10.1038/onc.2012.288 · Cited by 165
Role of exon-16-deleted HER2 in breast carcinomas
Castiglioni, F., Tagliabue, E., Campiglio, M., Pupa, S. M., Balsari, A., & Ménard, S. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01047 · Cited by 165
Modification of Alternative Splicing of Bcl-x Pre-mRNA in Prostate and Breast Cancer Cells
Mercatante, D. R., Bortner, C. D., Cidlowski, J. A., & Kole, R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009256200 · Cited by 163
Splicing factor SRSF6 promotes hyperplasia of sensitized skin
Jensen, M. A., Wilkinson, J. E., & Krainer, A. R. (2014) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2756 · Cited by 162
Mavrou, A., Brakspear, K., Hamdollah-Zadeh, M., Damodaran, G., Babaei-Jadidi, R., Oxley, J., Gillatt, D. A., Ladomery, M. R., Harper, S. J., Bates, D. O., et al. (2015) · Oncogene · doi:10.1038/onc.2014.360 · Cited by 162
Johnston, J. J., Teer, J. K., Cherukuri, P. F., Hansen, N. F., Loftus, S. K., Chong, K., Mullikin, J. C., & Biesecker, L. G. (2010) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2010.04.007 · Cited by 161
Global analysis of alternative splicing during T-cell activation
Ip, J. Y., Tong, A., Pan, Q., Topp, J. D., Blencowe, B. J., & Lynch, K. W. (2007) · RNA · doi:10.1261/rna.457207 · Cited by 161
Splicing factor hnRNPH drives an oncogenic splicing switch in gliomas
LeFave, C. V., Squatrito, M., Vorlová, S., Rocco, G., Brennan, C., Holland, E. C., Pan, Y., & Cartegni, L. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.259 · Cited by 160
Cotranscriptional exon skipping in the genotoxic stress response
Dutertre, M., Sanchez, G., De Cian, M.-C., Barbier, J., Dardenne, E., Gratadou, L., Dujardin, G., Le Jossic-Corcos, C., Corcos, L., & Auboeuf, D. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1912 · Cited by 160
The RNA-binding protein HuR is essential for the B cell antibody response
Diaz-Muñoz, M. D., Bell, S. E., Fairfax, K., Monzon-Casanova, E., Cunningham, A. F., Gonzalez-Porta, M., Andrews, S. R., Bunik, V. I., Zarnack, K., Curk, T., et al. (2015) · Nature Immunology · doi:10.1038/ni.3115 · Cited by 159
M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth
Cortés-Cros, M., Hemmerlin, C., Ferretti, S., Zhang, J., Gounarides, J. S., Yin, H., Muller, A., Haberkorn, A., Chene, P., Sellers, W. R., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1212780110 · Cited by 159
The splicing factor SRSF6 is amplified and is an oncoprotein in lung and colon cancers
Cohen‐Eliav, M., Golan‐Gerstl, R., Siegfried, Z., Andersen, C. L., Thorsen, K., Orntoft, T. F., Mu, D., & Karni, R. (2012) · The Journal of Pathology · doi:10.1002/path.4129 · Cited by 159
Small Molecule Modulators of Pre-mRNA Splicing in Cancer Therapy
Salton, M., & Misteli, T. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.11.005 · Cited by 159
SC35 Plays a Role in T Cell Development and Alternative Splicing of CD45
Wang, H., Xu, X., Ding, J.-H., Bermingham, J. R., & Fu, X. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00181-2 · Cited by 158
Venables, J. P., Brosseau, J., Gadéa, G., Klinck, R., Prinos, P., Beaulieu, J., Lapointe, E., Durand, M., Thibault, P., Tremblay, K., et al. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.01174-12 · Cited by 158
Nonsense-mediated mRNA Decay and Cancer
Popp, M. W., & Maquat, L. E. (2017) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2017.10.007 · Cited by 157
Chang, C., Goel, H. L., Gao, H., Pursell, B. M., Shultz, L. D., Greiner, D. L., Ingerpuu, S., Patarroyo, M., Cao, S., Lim, E., et al. (2015) · Genes & Development · doi:10.1101/gad.253682.114 · Cited by 156
Splicing factor mutations and cancer
Yoshida, K., & Ogawa, S. (2014) · WIREs RNA · doi:10.1002/wrna.1222 · Cited by 155
Identification of recurrent regulated alternative splicing events across human solid tumors
Danan-Gotthold, M., Golan‐Gerstl, R., Eisenberg, E., Meir, K., Karni, R., & Levanon, E. Y. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv210 · Cited by 155
Alternative Splicing of Rac1 Generates Rac1b, a Self-activating GTPase
Fiegen, D., Haeusler, L. C., Blumenstein, L., Herbrand, U., Dvorský, R., Vetter, I. R., & Ahmadian, M. R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310281200 · Cited by 155
Ishii, H., Saitoh, M., Sakamoto, K., Kondo, T., Katoh, R., Tanaka, S., Motizuki, M., Masuyama, K., & Miyazawa, K. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.589432 · Cited by 153
Regulation of alternative splicing of Bcl-x by BC200 contributes to breast cancer pathogenesis
Singh, R., Gupta, S. C., Peng, W.-X., Zhou, N., Pochampally, R. R., Atfi, A., Watabe, K., Lü, Z., & Mo, Y.-Y. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.168 · Cited by 150
Akgül, C., MOULDING, D. A., & Edwards, S. W. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4001-7 · Cited by 149
Cittelly, D. M., Das, P. M., Salvo, V. A., Fonseca, J. P., Burow, M. E., & Jones, F. E. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq192 · Cited by 149
Novel Splicing Factor RBM25 Modulates Bcl-x Pre-mRNA 5′ Splice Site Selection
Zhou, A., Ou, A. C., Cho, A., Benz, E. J. J., & Huang, S.-C. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00560-08 · Cited by 146
Gallardo, M., Lee, H. J., Zhang, X., Bueso-Ramos, C., Pageon, L. R., McArthur, M., Multani, A., Nazha, A., Manshouri, T., Parker-Thornburg, J., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.09.001 · Cited by 145
Mcl-1 Regulation and Its Role in Multiple Myeloma
Gouill, S. L., Podar, K., Harousseau, J., & Anderson, K. C. (2004) · Cell Cycle · doi:10.4161/cc.3.10.1196 · Cited by 145
Body Temperature Cycles Control Rhythmic Alternative Splicing in Mammals
Preußner, M., Goldammer, G., Neumann, A., Haltenhof, T., Rautenstrauch, P., Müller-McNicoll, M., & Heyd, F. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.06.006 · Cited by 145
Duncan, P. I., Stojdl, D. F., Marius, R. M., Scheit, K. H., & Bell, J. C. (1998) · Experimental Cell Research · doi:10.1006/excr.1998.4083 · Cited by 143
Building Robust Transcriptomes with Master Splicing Factors
Jangi, M., & Sharp, P. A. (2014) · Cell · doi:10.1016/j.cell.2014.09.054 · Cited by 141
Auto- and Cross-Regulation of the hnRNP L Proteins by Alternative Splicing
Rossbach, O., Hung, L.-H., Schreiner, S., Grishina, I., Heiner, M., Hui, J., & Bindereif, A. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01689-08 · Cited by 141
Anti-tumor activity of splice-switching oligonucleotides
Bauman, J. A., Li, S., Yang, A., Huang, L., & Kole, R. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq731 · Cited by 141
Koizumi, J., Okamoto, Y., Onogi, H., Mayeda, A., Krainer, A. R., & Hagiwara, M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.16.11125 · Cited by 140
Up-regulation of the proapoptotic caspase 2 splicing isoform by a candidate tumor suppressor, RBM5
Fushimi, K., Ray, P., Kar, A. N., Wang, L., Sutherland, L. C., & Wu, J. Y. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805569105 · Cited by 140
A novel splice variant ofHER2 with increased transformation activity
Kwong, K. Y., & Hung, M. (1998) · Molecular Carcinogenesis · Cited by 139
Rbfox2 controls autoregulation in RNA-binding protein networksPreprint
Jangi, M., Boutz, P. L., Paul, P., & Sharp, P. A. (2014) · Genes & Development · doi:10.1101/gad.235770.113 · Cited by 139
Dittmar, K. A., Jiang, P., Park, J. W., Amirikian, K., Wan, J., Shen, S., Xing, Y., & Carstens, R. P. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.06536-11 · Cited by 139
hnRNP H and hnRNP F Complex with Fox2 To Silence Fibroblast Growth Factor Receptor 2 Exon IIIc
Mauger, D., Lin, C. P., & García-Blanco, M. A. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00739-08 · Cited by 139
Zhou, Z., Dai, Z., Zhou, S., Fu, X., Zhao, Y., Shi, Y., Zhou, J., & Fan, J. (2012) · International Journal of Cancer · doi:10.1002/ijc.27742 · Cited by 138
Cited by
Roles and mechanisms of alternative splicing in cancer — implications for care
Bonnal, S. C., López-Oreja, I., & Valcárcel, J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0350-x · Cited by 731
Extracellular matrix (ECM) stiffness and degradation as cancer drivers
Najafi, M., Farhood, B., & Mortezaee, K. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27681 · Cited by 715
RNA splicing dysregulation and the hallmarks of cancer
Bradley, R. K., & Anczuków, O. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00541-7 · Cited by 579
Self-citationVitting-Seerup, K., & Sandelin, A. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz247 · Cited by 338
Alternative splicing and related RNA binding proteins in human health and disease
Tao, Y., Zhang, Q., Wang, H., Yang, X., & Mu, H. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01734-2 · Cited by 320
Metadata
- Authors
- Urbanski, L. M., Leclair, N., & Anczuków, O.
- Venue
- WIREs RNA
- Publisher
- Wiley
- Published
- 2018-04-25
- Volume
- 9
- Issue
- 4
- Pages
- e1476-e1476
- ISSN
- 1757-7004 (ISSN-L)
- 1757-7012
- OpenAlex
- W2800987064
- Cited by
- 389
- References
- 420
- FWCI
- 3.45
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.